November 13, 2026 10:02 AM 2 min read
Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
by Vandana Singh Benzinga Staff Writer
Follow
PFEPfizer Inc
$28.77-0.19%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
Momentum78.19
Growth2.12
Quality23.36
Value26.99
Price Trend
ShortMediumLongOverview Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its vaginal cream and three oral tablet strengths.
Pfizer Canada confirmed to Reuters on Thursday that it will supply no further batches of Premarin vaginal cream, which treats menopause symptoms and has experienced shortages in Canada since June.
Menopause Drug Shortages Strain Canadian Supply
The discontinuation of Premarin products, alongside shortages of certain estradiol patches, could add pressure on Canada’s menopause…